Treatment of high-risk chronic GVHD.
Pavletic
Steven
S
National Cancer Institute, Bethesda, Maryland, USA.
Vogelsand
Georgia B
GB
D000208:Acute Disease; D000328:Adult; D002908:Chronic Disease; D003875:Drug Eruptions; D005260:Female; D006086:Graft vs Host Disease / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation; D012306:Risk; D013256:Steroids / Q000008:administration & dosage / Q000009:adverse effects; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D013256:Steroids; D016559:Tacrolimus